Form 4: Nurix CSO Exercises Options, Boosts Stake

Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, exercised stock options to acquire 31,333 shares of common stock at $0.84 per share.

Summary

• Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc. (NRIX), exercised employee stock options.
• The transaction occurred on February 3, 2026.
• A total of 31,333 shares of common stock were acquired at an exercise price of $0.84 per share.
• Following this transaction, Gwenn Hansen directly beneficially owns 115,005 shares of Nurix Therapeutics common stock.
• The exercised option was fully vested prior to the transaction.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. An executive increasing their direct ownership through option exercise demonstrates confidence in the company's future performance and valuation.

Positives

• Gwenn Hansen, a key executive, increased her direct ownership in Nurix Therapeutics, signaling confidence in the company's future prospects.
• The exercise of options at a low price of $0.84 per share suggests a belief that the current market value or future value of the stock is significantly higher.

Industry Context

StockSavvy.ai notes that insider transactions, particularly option exercises that increase an executive's direct stake, are often viewed by the market as a positive signal. This action by Nurix's Chief Scientific Officer suggests continued commitment and belief in the company's long-term value, which can be a reassuring sign for investors in the biotechnology sector.

Stakeholder Impact

• Shareholders may view this increase in insider ownership as a positive indicator of management's belief in the company's future, potentially boosting investor confidence.

Key Dates

Recommendation

The exercise of stock options by a key executive, Gwenn Hansen, to increase her direct ownership in Nurix Therapeutics is a positive signal, indicating confidence in the company's future. While not a direct market purchase, it reflects a belief in the stock's potential appreciation from the exercise price. This action supports a 'hold' recommendation, suggesting investors maintain their positions, as it signals internal conviction without providing new fundamental data for a 'buy' or 'sell' decision.

Keywords

Nurix Therapeutics, NRIX, Gwenn Hansen, Chief Scientific Officer, Insider Transaction, Stock Option Exercise, Beneficial Ownership, Form 4, Equity Compensation